Literature DB >> 12376806

Cobalamin C deficiency complicated by an atypical glomerulopathy.

Steven M Brunelli1, Kevin E C Meyers, Marta Guttenberg, Paige Kaplan, Bernard S Kaplan.   

Abstract

Cobalamin C (cbl C) deficiency, an inherited disorder of vitamin B12 metabolism, causes elevated levels of methylmalonic acid and homocysteine and decreased methionine in all body fluids. Renal complications of cbl C disease are thrombotic microangiopathy (TMA), chronic renal failure, tubulointerstitial nephritis and proximal renal tubular acidosis. There is, however, only one case report of primary glomerular pathology, focal segmental glomerulosclerosis, in a cbl C deficient patient. We report a case of an atypical glomerulopathy in a 16-year-old male patient with cbl C deficiency. The glomerulopathy manifested with proteinuria and progressive renal insufficiency. The renal histologic, immunofluorescent and ultrastructural findings were similar, but not identical, to idiopathic membranoproliferative glomerulonephritis (MPGN) but also overlapped with those of a TMA. The serum complement profile was normal; there were scanty glomerular deposits of C3, no deposits of IgG and ultrastructural findings that were similar to those seen in either MPGN type III or a TMA. On the basis of these findings we have designated the renal disease as an atypical glomerulopathy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12376806     DOI: 10.1007/s00467-002-0895-1

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  19 in total

Review 1.  Renal dysfunction in methylmalonic acidurias: review for the pediatric nephrologist.

Authors:  Marina A Morath; Friederike Hörster; Sven W Sauer
Journal:  Pediatr Nephrol       Date:  2012-07-20       Impact factor: 3.714

2.  An unusual cause of hypertension with hematuria and proteinuria: Answers.

Authors:  Michael B Stokes; Ronald Zviti; Fangming Lin; Vivette D D'Agati
Journal:  Pediatr Nephrol       Date:  2016-03-15       Impact factor: 3.714

3.  Atypical adult-onset methylmalonic acidemia and homocystinuria presenting as hemolytic uremic syndrome.

Authors:  David Navarro; Ana Azevedo; Sílvia Sequeira; Ana Carina Ferreira; Fernanda Carvalho; Teresa Fidalgo; Laura Vilarinho; Maria Céu Santos; Joaquim Calado; Fernando Nolasco
Journal:  CEN Case Rep       Date:  2018-01-02

4.  Nephrotic syndrome and thrombotic microangiopathy caused by cobalamin C deficiency.

Authors:  Jens C Koenig; Frank Rutsch; Clemens Bockmeyer; Matthias Baumgartner; Bodo B Beck; Brigitta Kranz; Martin Konrad
Journal:  Pediatr Nephrol       Date:  2015-04-18       Impact factor: 3.714

Review 5.  Combined methylmalonic acidemia and homocystinuria, cblC type. II. Complications, pathophysiology, and outcomes.

Authors:  Nuria Carrillo-Carrasco; Charles P Venditti
Journal:  J Inherit Metab Dis       Date:  2011-07-12       Impact factor: 4.982

Review 6.  Combined methylmalonic acidemia and homocystinuria, cblC type. I. Clinical presentations, diagnosis and management.

Authors:  Nuria Carrillo-Carrasco; Randy J Chandler; Charles P Venditti
Journal:  J Inherit Metab Dis       Date:  2011-07-12       Impact factor: 4.982

Review 7.  Cobalamin C defect: natural history, pathophysiology, and treatment.

Authors:  Diego Martinelli; Federica Deodato; Carlo Dionisi-Vici
Journal:  J Inherit Metab Dis       Date:  2010-07-15       Impact factor: 4.982

8.  Hemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder.

Authors:  Ajay P Sharma; Cheryl R Greenberg; Asuri N Prasad; Chitra Prasad
Journal:  Pediatr Nephrol       Date:  2007-09-14       Impact factor: 3.714

Review 9.  Methylmalonic and propionic acidemias: clinical management update.

Authors:  Jamie L Fraser; Charles P Venditti
Journal:  Curr Opin Pediatr       Date:  2016-12       Impact factor: 2.856

10.  Atypical glomerulopathy associated with the cblE inborn error of vitamin B₁₂ metabolism.

Authors:  Erin A Paul; Marta Guttenberg; Paige Kaplan; David Watkins; David S Rosenblatt; James R Treat; Bernard S Kaplan
Journal:  Pediatr Nephrol       Date:  2013-03-19       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.